Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)

被引：0
|
作者：
Wang, Jianxiang [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ]
Huang, Xiaojun
Hu, Jianda
Li, Jianyong
Jin, Jie
Meng, Fanyi
Shen, Zhixiang
Liu, Ting
Wu, Depei
Wang, Jianmin
机构：
[1] Chinese Acad Med Sci, Inst Hematol, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Beijing, Peoples R China
[3] Peking Univ, Inst Hematol, Beijing, Peoples R China
[4] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[5] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[6] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[7] Jiangsu Prov Hosp, Suzhou, Peoples R China
[8] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[9] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[10] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai, Peoples R China
[11] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[12] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[13] Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2013年 / 54卷
关键词：
CML; dasatinib; imatinib-resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3
引用
收藏
页码：3 / +
页数：3
相关论文
共 50 条
  • [21] Dasatinib as initial therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    O'Brien, Susan
    Luthra, Raja
    Jabbour, Elias
    Quintas-Cardama, Aflonso
    Borthakur, Gautam
    Ravandi, Farhad
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge
    CANCER RESEARCH, 2011, 71
  • [22] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [23] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
    Hoyle, Martin
    Rogers, Gabriel
    Moxham, Tiffany
    Liu, Zulian
    Stein, Ken
    VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
  • [24] Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
    Usala, Emilio
    CLINICAL MANAGEMENT ISSUES, 2011, 5 : 27 - 30
  • [25] DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL
    Zwaan, C. M.
    Kearns, P.
    Lee, M. L. D. M.
    De Souza, C. A.
    Bertrand, Y.
    Hijiya, N.
    Stork, L.
    Chung, N-G
    Cardos, R. Cardenas
    Saikia, T.
    Fagioli, F.
    Seo, J. J.
    Landman-Parker, J.
    Lancaster, D.
    Place, A. E.
    Rabin, K. R.
    Sacchi, M.
    Swanink, R.
    Gore, L.
    HAEMATOLOGICA, 2017, 102 : 150 - 151
  • [26] USING OF DASATINIB FOR TREATMENT IMATINIB-RESISTANT AND IMATINIB-INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. RUSSIAN EXPERIENCE OF DASATINIB TREATMENT
    Khoroshko, N.
    Vinogradova, O.
    Turkina, A.
    Voroncova, A.
    Chelysheva, E.
    Gusarova, G.
    Kuznetsov, S.
    Gorjacheva, S.
    Sokolova, M.
    Abakumov, E.
    Lazareva, O.
    Domracheva, E.
    Misyurin, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 539 - 539
  • [27] THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO
    Juarez-Garcia, A.
    Uc-Coyoc, R.
    Hernandez-Rivera, G.
    Rangel, S.
    Taylor, M. J.
    Litalien, G.
    Donato, B.
    VALUE IN HEALTH, 2009, 12 (07) : A495 - A495
  • [28] Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis J.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Branford, Susan
    Mueller, Martin C.
    Shou, Yaping
    Novick, Steven
    Fan, Xiaolin
    Cortes, Jorge E.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1610 - 1610
  • [29] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukaemia in chronic phase (CML-CP): updated phase 2 results
    Clark, R.
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    le Coutre, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 57 - 58
  • [30] Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
    Al-Ameri, Ali
    Kantarjian, Hagop
    Borthakur, Gautam
    Bahceci, Erkut
    Szatrowski, Ted
    Damokosh, Andrew
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 459 - 459
12345